WCN26-2995 SERUM LEVELS OF EphA2, A TYROSINE KINASE RECEPTOR, MAY SERVE AS A BIOMARKER FOR RENAL IMPAIRMENT AND TREATMENT RESPONSE IN IgA NEPHROPATHY

Read full text Summarise with VIRAT
Authors: Kenichiro Abe, Maki Murakoshi, Takumi Iwasawa, Kazunori Kato, Yusuke Suzuki, Tomohito Gohda
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Erythropoietin-producing hepatoma A2 (EphA2), a member of the Eph family of receptor tyrosine kinases, has been implicated in inflammation and atherosclerotic diseases. Because EphA2 has been reported to participate in kidney and cardiovascular diseases, this study aimed to investigate the relationship between serum EphA2 levels and renal function in individuals with IgA nephropathy. In addition, we evaluated the potential of EphA2 as a biomarker reflecting histological severity and treatment response.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Systemic Lupus Erythematosus Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104432–104432
Publication date
25 March 2026
Language
EN